Performance, transparency, trust

We’re proud of the value we create for all our stakeholders, and strive to communicate our performance in a clear and timely manner. Download the latest reports, or stay up to date on various metrics of our market performance here. If you have any queries not addressed here, please feel free to get in touch with Investor Relations on our Contact page. 


Observe Medical ASA was listed on Oslo Børs 4 November 2019. Our ambition is to provide shareholders, analysts and investors simultaneous access to accurate, clear and relevant information. We aim to make all our communication to the financial market available on this web site. 

Read our latest regulatory news

Observe Medical ASA (OBSRV) – Financial calendar

FINANCIAL YEAR 2021 03.11.2021 – Quarterly Presentation – Q3 17.02.2022 – Quarterly Presentation – Q4 29.04.2022 – Annual Report 02.06.2022 – Annual General Meeting FINANCIAL YEAR 2022 12.05.2022 – Quarterly Presentation – Q1 25.08.2022 – Second quarter and Half-year Report 03.11.2022 – Quarterly Report – Q3 This information is published pursuant to the requirements set out…

Read more

Observe Medical ASA: Interim report for the second quarter and first half-year 2021

Oslo, August 20[th], 2021 – Observe Medical ASA (OSE: OBSRV) today released its financial results and presentation of the second quarter and first half-year of 2021, reporting continuous progress in the go-to-market execution for Sippi®, a unique and proprietary solution for digital, automated urine monitoring. “We have a sharp focus on continuous roll-out of Sippi®,…

Read more

Observe Medical ASA : Invitation to second quarter and first half year 2021 presentation

Observe Medical ASA invites you to a presentation of the second quarter and first half year 2021. The presentation will take place at Felix Konferansesenter in Oslo on Friday, August 20th. The event will start at 08.30 CET and will be webcasted live on – Investor relations and at the following link:  …

Read more

Financial calendar

  • 30.04.21

    Annual Report

  • 12.05.21

    Quarterly Presentation - Q1

  • 21.05.21

    Annual General Meeting

  • 20.08.21

    Half-yearly Report

  • 03.11.21

    Quarterly Presentation - Q3

The Share

Share performance


Last updated 4 October 2021

NameNumber of shares% of top 20% of totalCountry
1NAVAMEDIC ASA 4,222,727  25.12%21.54%Norway
2INGERØ REITEN INV. COMPANY AS 3,939,394  23.43%20.09%Norway
3RO, LARS 1,501,051  8.93% 7.66%NORWAY
5ARTAL AS 1,064,457 6.33% 5.43%Norway
6ALPINE CAPITAL AS 745,446 4.43% 3.80%Norway
7Soleglad Invest AS 586,668 3.49% 2.99% NORWAY
8NORDA ASA 511,632 3.04% 2.61%NORWAY
9TRANBERGKOLLEN INVEST AS 500,000  2.97% 2.55%Norway
10LEIKERANE AS 373,439  2.22% 1.90%Norway
11LAPAS AS 348,326 2.07% 1.78%Norway
12GINNY INVEST AS 270,030 1.61% 1.38%NORWAY
13PHILIP HOLDING AS 260,000 1.55% 1.33%NORWAY
15cam as 181,000 1.08% 0.92%NORWAY
16mp pENSJON PK 176,135 1.05% 0.90%NORWAY
17NORDNET BANK AB 138,618 0.82% 0.71%SWEDEN
18BJØRNTVEDT, VEGARD 123,253 0.73% 0.63%NORWAY
19ABC INVEST AS 120,000 0.71% 0.61%NORWAY
20EILERAAS, KARL ANSKAR 115,013 0.68% 0.59%Norway
Total numBer owned by top 2016,810,561100.00%85.74%
Total number of shares19,605,457

Basic share data

Stock Exchange:


First day of listing:


Trading Currency:


Number of shares issued:

Nominal value:

Euronext Expand Oslo


4 November 2019




19 605 457

NOK 0.26


Nomination committee

The Articles of Association provide for a nomination committee composed of two or three members. The current members of the nomination committee are Bård Brath Ingerø (chair) and Grete Hogstad.

The nomination committee is responsible for nominating candidates for the election of shareholder-elected members and chairperson to the Board of Directors and for nominating members to the nomination committee, as well as making recommendations for remuneration of these.

For nomination committee please contact:
Bård Brath Ingerø, Chair of the Nomination Committee
+47 92 83 33 34 /

IR contact

Björn Larsson, Chief Executive Officer
+46 766 201 725 /

Per Arne Nygård, Chief Financial Officer
+47 41 10 43 45 /

Sign up for the mailing list